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Summary A fluorinated 2-nitroimidazole radiosensitizer KU-2285 was given before intraoperative radiotherapy (IORT) to 30 patients with
unresectable, unresected or macroscopic residual tumours. Twenty-three patients had pancreatic cancer and five had osteosarcoma. The
IORT dose was 30 Gy for unresectable pancreatic cancer and 60 Gy for osteosarcoma. The dose of KU-2285 administered ranged from
1 to 9 g m-2. Four patients received a dose of 9 g m-2, and ten received 6.8-7 g m-2. All patients tolerated KU-2285 well, and no drug-related
toxicity was observed. The average tumour concentration of KU-2285 immediately after IORT was 166 jg g-1 at dose of 6.8-7 g m-2 and
333 jg g-1 at 9 g m-2. The averagetumour-plasma ratio was .0.82. Eleven patients with unresectable but localized pancreatic cancertreated
with KU-2285 plus IORT and external beam radiotherapy had a median survival time of 11 months and 1-year local control rate of 50%, which
compares favourably with those of 8 months (P = 0.26) and 28% (P= 0.10) for 22 matched historical control patients. The five patients with
osteosarcoma attained local control. The results of this first study on KU-2285 and IORT appear encouraging, and further studies of this
compound seem to be warranted.
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Of the many hypoxic cell radiosensitizers that have been devel-
oped in the laboratory, several have been tested in clinical studies.
A 2-nitroimidazole derivative, misonidazole, is the most widely
investigated compound (Adams, 1978), but after extensive clinical
studies this compound was deemed to be unsuitable for further
evaluation because of its neurotoxicity and the negative results in
most trials with the exception of a Danish head and neck cancer
study (Urtasun et al, 1984; Overgaard, 1994). After misonidazole,
two improved 2-nitroimidazole derivatives, etanidazole and
pimonidazole, were developed. Although pimonidazole later
proved to be unsuitable for clinical use because of its vasoactive
effect (Dische et al, 1993), etanidazole was found to be much less
toxic than misonidazole (Coleman et al, 1990). However, in the
recent phase II and III studies of this compound in combination
with external beam conventional radiotherapy, the outcomes ofthe
etanidazole-treated patients were not significantly better than
those of the patients treated with radiotherapy alone (Lee et al,
1995; Lawton et al, 1996). Owing to reoxygenation of hypoxic
tumourcells during fractionated radiotherapy, relatively low sensi-
tizing effects attolerable drug doses andpossible inclusion ofonly
slightly hypoxic tumours into clinical trials, the effect of hypoxic
cell sensitizers may be barely detectable when they are combined
with conventional fractionated radiotherapy (Brown, 1995). In
contrast, hypoxic cell sensitizers would more readily show their
effects when they are combined with single high-dose radio-
therapy. In this respect, intraoperative radiotherapy (IORT) seems
to be an optimal method ofachieving the maximum benefit from a
hypoxic cell sensitizer.
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KU-2285 is a fluorinated 2-nitroimidazole derivative developed
by the Kyoto University group (Shibamoto et al, 1989). It has a
CH2CF2CONHC2H4OH substituent at the N' position of the 2-
nitroimidazole ring. Preclinical laboratory studies have shown that
it has sensitizing activity higher than that of etanidazole both in
vitro and in vivo, although it is not evidently more toxic than
etanidazole (Sasai et al, 1991; Shibamoto et al, 1992; Oya et al,
1993; Shibata et al, 1994). Importantly, as KU-2285 has relatively
high lipophilicity (partition coefficient in octanol/water = 0.25)
(Sasai et al, 1991), the drug can be given orally and betterpenetra-
tion through the tumour tissue can be expected.
Based on these favourable characteristics of KU-2285 as a
hypoxic cell sensitizer, we planned to perform clinical studies of
this compound, but no pharmaceutical company was willing to
support the clinical study. Therefore, we carried out our own
preliminary clinical studies of this compound. The studies
consisted of one study in combination with external beam radio-
therapy and another study in combination with IORT. The results
of the former study have been reported recently (Shibamoto et al,
1996a). This report describes the results ofthe study with IORT.
MATERIALS AND METHODS
Study design
Permission was obtained from the institutional ethics committee to
perform a 3-year study of KU-2285 from 1993 to 1995 at Kyoto
University Hospital. All patients who were deemed eligible to
undergo IORTforunresectable, unresected ormacroscopic residual
tumours were considered eligible, and all 34 patients seen during
this period were enrolled in this study. Informed consent was
obtained from all patients. Of these patients, two were assessed as
unsuitable for IORT at laparotomy because of the advanced stage
of their disease, and two others underwent macroscopic curative
surgery. Therefore, these four patients were not given KU-2285,
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and the remaining 30 patients received KU-2285. The dose was
increased incrementally starting from 1 g mi-2. After the maximum
dose (9g m-2) was reached, the 7g m-2 dose was chosen to
continue the study. This study did not follow the guidelines of a
formal phase I study in every way because the study period was
limited and the accrual ofrelatively few patients was expected.
Patients
The characteristics ofthe 30 patients are shown in Table 1. Ofthe
30 patients, 23 had pancreatic cancer (22 with unresectable lesion
and one with macroscopic residual lesion) and five had osteo-
sarcoma. The osteosarcoma lesions could have been removed by
amputation of the limb, but we used IORT to save the affected
limb (Yamamuro et al, 1991).
KU-2285
KU-2285 was prepared by the group led by Professor S Nishimoto
at the Laboratory of Excited-State Hydrocarbon Chemistry,
Graduate School of Engineering, Kyoto University. As the
compound has not been prepared forintravenous administration, it
was given orally before anaesthetization in one patient or through
the gastric tube after anaesthetization in 29 patients. In the latter
instance, the compound was dissolved in saline at the maximum
soluble concentration of 5%. For determination of the drug
concentration in plasma and tumour by high-performance liquid
chromatography (HPLC), 1 ml of peripheral arterial blood was
obtained from each patient during operative procedures at 0.5, 1,
2, and 3 h after drug administration whenever possible and 5-
50 mg of tumour tissue was biopsied immediately after IORT.
Afterthe blood samples were centrifuged at3000r.e.m. for 10 min
to separate serum and the tumour was weighed, the samples were
stored at -20°C. Before HPLC analysis, serum and tumour
homogenates were extracted with methanol. HPLC analysis was
Table 1 Patient characteristics
Total number of patients 30
Male/female 21/9
Age (years)
Median 59
Range 10-73
Performance statusa
0 1
1 11
2 16
3 2
Tumour
Pancreas
Unresectable, localized 11
Unresectable, with distant metastasis 11
Macroscopic residual 1
Stomach
Macroscopic residual 1
Osteosarcoma
Unresected 5
Bladder
Unresected 1
aAccording to the World Health Organization standard.
performed using an ODS-2 column (4.6 x 150 mm, C18, particle
size 5 gm, GL Science Inertsil) and the flow rate was 1.0 ml min-'.
The eluents were CH3CN:H20 (10:50), 0.01 mol dm-3 NaH2PO4,
H3PO4. The drug absorbance peak was detected at 325 nm and the
retention time was 5.7 min.
IORT
Our method for IORT has been described previously (Yamamuro
et al, 1991; Shibamoto et al, 1996b). Briefly, unresectable pancre-
atic cancers were irradiated with 18- or20-MeV electron beams up
to a total dose of 30 Gy at a dose rate of 2 Gy min-'. In most
patients, 12-15 Gy was delivered first to a larger field (usually 6-
7 cm in diameter) covering the tumour plus a margin including a
part of the gastrointestinal tract, and then the remaining dose was
given to a smaller field with no margin (4-5 cm in diameter).
Conventional external beam radiotherapy up to a total dose of
40-55 Gy was added in patients with no distant metastasis. In five
patients with distant metastasis, preoperative radiation with total
doses of 20-30 Gy was given because no metastasis was detected
before IORT, but none of the patients with distant metastasis
received post-operative radiotherapy. The two patients with
macroscopic residual pancreatic or gastric cancer were given irra-
diation with 12 or 18 MeV electrons up to a dose of25 and 15 Gy
respectively. They also received external beam radiation with
45 Gy and 50 Gy respectively. For osteosarcoma, the overlying
skin was widely opened, the major muscles, vessels and nerves
were detached, and the lesions were irradiated with 10-MV X-rays
to atotal dose of60 Gy using twoparallel opposing fields at adose
rate of 5 Gy min-m. In one bladder cancer patient, an incision was
made in the bladder wall and a dose of 30 Gy was given to the
tumour using 8 MeV electron beams. The osteosarcoma and
bladder cancer patients received no external beam radiotherapy.
The survival and local control rates of the patients were calcu-
lated from the date ofIORT using the Kaplan-Meier method. Data
were also analysed for matched historical controls, comprising 22
patients with unresectable localized pancreatic cancer treated by
similar IORT and external beam radiotherapy before 1993 at
Kyoto University. Differences between pairs of survival or local
control curves were examined by the generalized Wilcoxon test. In
pancreatic cancer, patients were deemed to have local recurrence
when the tumour size became larger than the pretreatment size on
computerized tomography or palpation, or abdominal/back pain
recurred or became worse. Otherwise, the tumour was deemed to
be under control.
RESULTS
KU-2285 administration and toxicity
The first patient with bladder cancer to be treated received a dose
of 1 g mi-2 orally before being anaesthetized. During the interval
between the treatments ofthe first and second patients in the series,
the 1 g mi-2 dose was confirmed to be safe in patients receiving KU-
2285 in combination with external beamradiotherapy (Shibamoto et
al, 1996a), so this dose was not used again; the second patient
received a dose of2 g n-2. As the optimal timing for IORT in terms
of the peak drug concentration was likely to be missed when KU-
2285 was given before anaesthesia in patients with pancreatic,
gastric, or bone tumours, all the subsequently treated patients
received KU-2285 via a gastric tube after anaesthesia. The drug was
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Figure 1 Plasma concentrations of KU-2285 in patients with pancreatic or
gastric cancer receiving KU-2285 doses of 4.5 g m-2 (EJ, n = 7), 6.8-7 g m-2
(A, n = 9), or 9 g m-2 (0, n = 4). Error bars represent s.e.
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Figure 2 Peak plasma concentrations (0) and tumour concentrations
immediately after IORT (x) of KU-2285 in patients with pancreatic or gastric
cancer
injected into the stomach in patients with osteosarcoma, but in all
other patients undergoing upper abdominal surgery it was injected
into the upperjejunum, either through the forwarded gastric tube or
directly from the anastomosis site ofbypass surgery. In the patients
with osteosarcoma, KU-2285 was injected when we estimated it
would be 1.5-2 h before IORT, and in the other patients it was
injected 1-1.5 h beforehand.
In the first dose-escalating process, the administered dose of
KU-2285 was 1 g m-2 in onepatient, 2 g m-2 in two, 3 g m-2 in three
and 4.5 g m-2 in ten. Considering the solubility of the compound
(5%), we initially thought that the dose of 4.5 g m-2 might be the
highest dose, as 120-150 ml ofsaline is necessary, but afterdiscus-
sion with anaesthesiologists we decided to increase the dose
further. Thereafter, four patients received a dose of 6.8 g m-2, and
then fourreceived 9 g m-2. No toxicity was observed. However, the
fourpatients receiving the 9-g m-2 dose were, by chance, relatively
small (1.14-1.35M2), and this dose was not considered to be
applicable to large patients because ofthe limited solubility ofthe
compound. Also, the tumour concentration of KU-2285 was suffi-
ciently high at the dose of 6.8 g m-2, and the dose of 7 g m-2 was
chosen to continue the study; six patients received this dose.
Drug-related toxicity was not observed in any of the patients.
After drug administration, there was no change in blood pressure
and no deterioration in the post-operative course. In addition, there
appeared to be no enhancement ofIORT effects on normal tissue.
However, there was a complication due to misadministration. In
one patient with osteosarcoma, the entire solution of 7 g m-2 KU-
2285 was erroneously injected into the trachea; his arterial oxygen
pressure dropped to 60 mmHg. After bronchoscopic suction of
part of the solution, the patient's condition recovered in about
45 minand there were no long-term effects.
Pharmacokinetics
Figure 1 shows plasma concentrations of KU-2285 after intra-
jejunal administration of4.5, 6.8-7 or 9 g m-2 ofthe compound in
the patients with pancreatic or gastric cancer. The plasma concen-
tration ofKU-2285 appeared to reach apeak after0.5-1 h ofintra-
jejunal administration in most patients and then it gradually
decreased. Figure 2 shows the peak plasma concentrations and
tumour concentrations immediately after IORT of KU-2285 as a
function ofthe administered dose inthe 24patients withpancreatic
orgastric cancer. In three patients, tumourbiopsy was not feasible.
The average peak plasma concentration was 136 gg ml-' at the
dose of 4.5 g m-2, 215 jg ml-' at 6.8-7 g m-2, and 301 jig ml' at
9 g m-2, and the average tumour concentration was 81, 166, and
333 jg g-' respectively. In the 21 patients with tumour biopsy, the
average tumour-plasma ratio was 0.82 ± 0.32 (s.d.), although the
true ratio may have been slightly higher because the tumour was
biopsied only once in each patient.
Pharmacokinetic data for the five osteosarcoma patients are
shown in Table 2 together with their treatment outcomes. In the
patients receiving intragastric administration of KU-2285 in the
supine position, the average peak plasma concentrations were
75-98% of those in the pancreatic or gastric cancer patients, in
whom KU-2285 was administered into the upperjejunum. In three
osteosarcoma patients, the timing of biopsy (and IORT) was
delayed due to the rather complicated IORT procedure, so the
exact tumour-plasma ratio was not evaluable. Interestingly, the
patient in whom the drug was administered intratracheally showed
high plasma levels ofKU-2285.
One patient with bladder cancer receiving oral KU-2285 at
1 gm-2showed apeakplasmaconcentration of 15 jg mll 2 h after
administration ofthe drug. Tumourbiopsy could not be performed
in this patient.
Treatment outcome
Of the 22 patients with unresectable pancreatic cancer, 11 had no
distant metastasis but 11 had liver metastasis and/or peritoneal
dissemination. Figure 3 shows the survival curve for the 11
patients with localized unresectable tumours together with that for
the 22 matched historical control patients. Although the difference
between the KU-2285 group and the control group was not signif-
icant (P = 0.26), the median survival time of 11 months for the
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Table 2 Characteristics of osteosarcoma patients treated with KU-2285 and IORT
KU-2285 level
KU-2285 Plasmaa Tumourb
Age dose (±g ml-,) (ig g-1)
(years) Sex Site (g m-2) [Time] [Time] Local status Status
10 F Humerus 3 65 31 Control 5 months, died of
[2 h] [3.5 h] lung metastasis
13 M Femur 4.5 130 33 Control 43 months, died of
[2 h] [4.5] 11 months prosthetic intercurrent disease
replacement
16 M Femur 4.5 147 91 Control 38 months, no
[2 h] [3 h] 9 months prosthetic evidence of disease
replacement
14 M Humerus 4.5 104 41C Control 34 months, no evidence
[1 h] [2 h] of disease
52 M Tibia 7d 289 - Control 15 months,
[2 h] no evidence of disease
aPeak plasma concentration; btumour concentration at 10-20 min after completion of IORT; cconcentration in peritumoural fattissue; din this patient, KU-2285
was erroneously injected into the trachea.
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Figure 3 Survival curves for the 11 patients with unresectable but localized
pancreatic cancer receiving KU-2285 plus IORT and external beam radiation
(-) and for the 22 matched historical control patients (...)
former group compares favourably with that of 8 months for the
latter. The 2-year survival rate was 18% vs 4.5%. One patient in
the KU-2285 group died of intercurrent disease at 25 months
without sign ofrecurrence. The 11 patients with distant metastasis
had a median survival time of 4 months (range 3-12 months),
which was similar to that (3.5 months) in the historical control
patients treated with IORT alone (Shibamoto et al, 1996b).
Figure 4 shows the local control curves for the 11 patients with
localized unresectable pancreatic cancer receiving KU-2285 and
for the 21 historical control patients. Local status was not assess-
able in one of the historical control patients. The 1- and 2-year
local control rates were 50% and 40% respectively for the KU-
2285 group, and both were 28% for the control group (P = 0.10).
In the 11 patients with distant metastasis, the actuarial local
control rate at 6 months was 44%.
There has been no local recurrence in the five patients with
osteosarcoma, although two ofthemunderwent ceramic prosthesis
replacement ofthe irradiated tumour 9-11 months laterbecause of
pathological fracture (Table 2). Fracture of the irradiated tumour
site is a common sequela ofthis treatment modality (Yamamuro et
Months
Figure 4 Local control curves for the 11 patients with unresectable but
localized pancreatic cancer receiving KU-2285 plus IORT and external beam
radiation (-) and for the 21 matched historical control patients (... ). Ticks
represent individual patients alive or dead without local recurrence
al, 1991). One patient with gastric cancer died ofperitonitis carci-
nomatosa 1 year later. One patient with non-curatively resected
pancreatic cancer is alive with high tumour marker levels but
without evidence oflocal recurrence at 15 months afterIORT. One
patient with bladder cancer attained local control until 5 months,
but then he was lost to follow-up.
DISCUSSION
It is well known that hypoxic cell sensitizers are most effective
when they are combined with single high-dose irradiation.
Accordingly, misonidazole and etanidazole have been investigated
in combination with IORT. Tepper et al (1987) used misonidazole
at a dose of 3.5 g m-2 in combination with IORT of 15-20 Gy for
localized unresectable pancreatic cancer. They compared 41
patients receiving misonidazole with 22 historical control patients
treated without misonidazole, but they did not find any significant
difference between the two groups in either the survival rate or
local control rate. This was anon-randomized comparison, and the
control group had smaller tumours than the misonidazole group.
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Indeed, the control group had a median survival time of 16.5
months, which is the longest one reported, so far, for unresectable
pancreatic cancer (Shibamoto et al, 1996c). Nevertheless, the 2-
year local control rate, as assessed by criteria similar to those used
in this study, in the misonidazole group (45%) was higher, though
not significantly so, than that in the control group (31%). Early
development ofdistant metastasis in most patients was considered
to obscure the possible benefit of misonidazole. For etanidazole,
only the results of a phase I study have been reported to date
(Halberg et al, 1994), and in that study most patients underwent
IORT after resection of primary tumours, for which reason no
information is available as to the efficacy of etanidazole. A 2-
nitroimidazole nucleoside analogue RK-28 was tested in Japan in
combination with IORT for mainly pancreatic cancer patients, but
the study was discontinued before accrual of a sufficient number
of patients to assess its efficacy (Sasai et al, 1992). A phase I trial
for unresectable pancreatic cancer of another 2-nitroimidazole
nucleoside analogue, PR-350 (Oya et al, 1995), is now on-going in
Japan, but results regarding its efficacy are not yet available. Thus,
no definite conclusions have been drawn as to the efficacy of
hypoxic cell sensitizers when combined with IORT.
Apparently, KU-2285 has characteristics different from etanida-
zole. Owing to its fluorination, it has higher sensitizing activity,
although its toxicity is similar. Because of its relatively high
lipophilicity, faster and better distribution of the compound
throughout tumour tissue can be expected. Therefore, we thought
that KU-2285 was worthy ofclinical evaluation. As this drug was
originally intended to be given exclusively orally, no intravenous
toxicity studies in large animals have been carried out and nophar-
maceutical examination has been performed to allow its intra-
venous use. Therefore, we administered the compound into the
jejunum or stomach, or orally. As partly expected from the results
of the phase I study in combination with conventional radio-
therapy, in which cumulative doses up to 28 g m-2 were tolerable
(Shibamoto et al, 1996a), we observed no toxicity of this
compound up to the dose of 9 g m-2. Because of the limited solu-
bility, we did not increase the dose further, but considered 7 g m-2
as the standard dose. These doses are lower than the maximum
dose of 12 g m-2 for etanidazole, but considering the afore-
mentioned characteristics of KU-2285, further studies of this
compound seem to be warranted.
Sufficiently high concentrations of KU-2285 to obtain definite
radiosensitization were achieved when itwas injected both into the
jejunum and into the stomach, although the levels appeared
slightly lower in the latter. The plasma levels of KU-2285 at 6.8-
9 g m-2 were higher than those of misonidazole (100 ,ug ml-' or
higher) obtained in the IORT study (Tepper et al, 1987), but lower
than the levels of etanidazole (700-1500 ,ug ml-') obtained at the
dose of 12 g m-2 (Halberg et al, 1994). This is partly because
etanidazole was given intravenously. However, the distribution of
KU-2285 into the tumour tissues was satisfactory. Although the
true tumour-plasma ratio may not have been determined, the
average ratio in pancreatic or gastric cancer patients was at least
0.82, which is higher than that (0.54) reported for etanidazole
(Halberg et al, 1994). The mean tumourconcentration ofKU-2285
was 166 jg g-1 after administration of 6.8-7 g m-2 and 333 jig g-'
after 9 g m-2. At these concentrations, sensitizer enhancement
ratios ofat least 1.8 can easily be expected (Kagiya et al, 1989).
Although a definite conclusion cannot yet be drawn as to the
efficacy of KU-2285 combined with IORT, the survival and
local control rates in the 11 patients with localized unresectable
pancreatic cancer compare favourably with those in our historical
control patients. The patient-tumour characteristics and the
IORT/external beam radiotherapy methods were similar in the two
groups. Curing such patients is still difficult, but it may be possible
to decrease or delay local recurrence by adding KU-2285 to IORT.
We will continue to use IORT with KU-2285 for unresectable
pancreatic cancer, as this treatment modality is not aggressive and
long-term survival is occasionally achieved. In the previous study
of misonidazole and IORT for unresectable pancreatic cancer
(Tepper et al, 1987), the IORT dose was 15-20 Gy, whereas we
used 30 Gy. In view ofthe higher doses ofboth the sensitizer and
radiation, the conditions in our study would have been more suit-
able to investigating the efficacy ofhypoxic cell sensitizers. In the
five patients with osteosarcoma, we used a 60-Gy dose, which is
usually sufficient to control osteosarcoma lesions (Yamamuro et
al, 1991), and we found no local failure. In future, it may be
possible to reduce this dose by the use ofthis compound.
In summary, we found no toxicity of KU-2285, when given
before IORT, up to a dose of 9 g m-2. Our preliminary results in
unresectable pancreatic cancer appear encouraging. Proceeding to
the next step seems to be appropriate. We are planning to combine
KU-2285 not only with IORT but also with radiosurgery.
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